NEW YORK, March 14, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:Cancer Monoclonal Antibodies Market to 2015
Globally, cancer is one of the leading causes of death, and accounted for almost 13% of total deaths in 2008. The cases of lung and breast cancers are expected to grow rapidly in the coming years. In order to treat the life-threatening disease more efficiently and with enhanced specificity, monoclonal antibodies have become the most widely used cancer therapy. As per the findings of our new research report, cancer monoclonal antibodies provide high specificity to treat tumors and several formats exist for the types of cancer monoclonal antibodies available.
According to "Cancer Monoclonal Antibodies Market to 2015", cancer monoclonal antibodies have evolved greatly from the first time they were implemented, and have created a strong demand since then. In the recent time, some very important monoclonal antibodies, such as Yervoy (ipilimumab) have entered the market. Our study expects that these antibodies will consume the share of leading monoclonal antibody products in the coming years.
Our research observed that the strong demand for effective cancer treatments and high prevalence are driving the cancer monoclonal antibodies market which is anticipated to grow at a CAGR of around 7% during 2012-2015. While research and innovation in this field have been growing exorbitantly, the industry has witnessed a large number of consolidation activities. In the report, we have also studied how technological advancements and a subsequent increase in number of approvals are influencing the market growth.
During the study of latest industry trends and drivers, we observed that conjugated cancer antibody therapies offer efficient cancer treatments. Besides, bispecific antibodies (BiAbs) present a unique opportunity to redirect immune effector cells to kill cancer cells. Our report covers the analysis of the entire monoclonal antibody market for cancer, and presents market forecasts for leading products. The geographic analyses for key markets, carried out in the research, foresee that the US and Europe will continue holding significant market shares, andJapan will exhibit unaltered double digit growth.
In our research report, we have conducted a comprehensive pipeline analysis of the expected cancer monoclonal antibodies and their phase of development. We found that maximum products are expected in the field of breast cancer in near future. The study discusses in detail the key market players, their business activities, key monoclonal antibody products which are available in the market and in pipeline. Overall, we expect the cancer monoclonal antibody market to show stupendous growth and great evolution in the coming years.
1. Analyst View2. Research Methodology3. The Global Burden of Cancer3.1 Cancer - A Leading Cause of Death3.2 Current and Future Cancer Cases: By Type and Geography3.3 Common Causes of Cancer4. Global Cancer Market Outlook to 20154.1 Current and Future Growth4.2 Analysis by Therapeutic Areas5. Monoclonal Antibodies: Introduction and Working5.1 Types of Mabs5.1.1 Murine Antibodies5.1.2 Chimeric and Humanized Antibodies5.1.3 Fully Human Antibodies5.2 Conjugated Cancer Therapies using MAbs5.2.1 Radioimmunotherapy5.2.2 Antibody-directed Enzyme Pro-drug Therapy (ADEPT)5.2.3 Immunoliposomes5.2.4 Immunotoxin5.2.5 Immunocytokine5.3 mAb Therapies5.3.1 Avastin/Bevacizumab5.3.2 Rituxan/Rituximab5.3.3 Herceptin/Trastuzumab5.3.4 Erbitux/Cetuximab5.3.5 Vectibix/Panitumumab5.3.6 Campath/Alemtuzumab5.3.7 Zevalin/ Ibritumomab5.3.8 Bexxar/Tositumomab5.3.9 Arzerra/Ofatumumab6. Industry Trends and Drivers6.1 Strategic Activity Building Up in the Market6.2 New Approvals Showing Promising Future6.3 Bispecific Antibodies: Emerging Therapeutic Treatment6.4 Japan Gearing-up for Cancer Antibodies7. Global Anti-Neoplastic mAbs Market Outlook to 20157.1 Market Size7.2 Anti-Neoplastic mAbs: Approval History and Market Share7.3 Anti-Neoplastic mAbs: Current and Future Market Size7.3.1 Avastin (Bevacizumab)7.3.2 MabThera/Rituxan (Rituximab)7.3.3 Herceptin (Trastuzumab)7.3.4 Erbitux (Cetuximab)7.3.5 Vectibix (Panitumumab)7.4 Country-Level Analysis7.4.1 US7.4.2 Japan7.4.3 Europe7.5 Market Share of Key Players8. Pipeline Analysis for Anti-Neoplastic Monoclonal Antibodies9. Competitive Landscape9.1 Roche9.2 Immunomedics9.3 Bristol-Myers Squibb9.4 AstraZeneca9.5 Eli Lilly9.6 Amgen
List of Figures:
Figure 3-1: Global - Leading Causes of Non-Communicable Deaths (%), 2008Figure 3-2: Global - Number of Cancer Deaths (Million), 2002, 2020 & 2030Figure 3-3: Global - Number of New Cancer Cases (Million), 2009 & 2020Figure 3-4: Global - New Cancer Cases by Region (%), 2009Figure 3-5: Global - Forecast for the New Cancer Cases by Region (%), 2020Figure 4-1: Global - Cancer Market (Billion US$), 2011-2015Figure 4-2: Global - Cancer Market by Player (%), 2011Figure 4-3: Global - Cancer Market by Therapeutic Segment (%), 2011Figure 5-1: Types of Monoclonal AntibodiesFigure 5-2: Hybridoma Technology for Mouse-derived Monoclonal AntibodiesFigure 7-1: Global - Anti-Neoplastic mAbs Market (Billion US$), 2011-2015Figure 7-2: Global - Anti-Neoplastic mAbs Market by Product (%), 2011Figure 7-3: Global - Avastin Sales (Billion US$), 2011-2015Figure 7-4: Global - MabThera/Rituxan Sales (Billion US$), 2011-2015Figure 7-5: Global - Herceptin Sales (Billion US$), 2011-2015Figure 7-6: Global - Erbitux Sales (Billion US$), 2011-2015Figure 7-7: Global - Vectibix Sales (Million US$), 2011-2015Figure 7-8: Global - Anti-Neoplastic mAbs Market by Country/Region (%), 2011Figure 7-9: US - Anti-Neoplastic mAbs Market (Billion US$), 2011-2015Figure 7-10: Japan - Anti-Neoplastic mAbs Market (Billion US$), 2011-2015Figure 7-11: Europe - Anti-Neoplastic mAbs Market (Billion US$), 2011-2015Figure 7-12: Global - Anti-Neoplastic mAbs Market by Player (%), 2011Figure 8-1: Global - Breakup of Anti-Neoplastic mAbs in Pipeline by Phase
List of Tables:
Table 3-1: Global - Number of New Cancer Cases by Type and Geography (2009)Table 3-2: Global - Forecast for the Number of New Cancer Cases by Type and Geography (2020)Table 4-1: Global - Revenues from Major Therapy Areas (Billion US$), 2011 & 2015Table 7-1: Global - List of FDA Approved Anti-Neoplastic mAbs with Year and IndicationTable 7-2: US - Forecast for the Number of Cancer Cases and Deaths by Types (2012)Table 7-3: US - Anti-Neoplastic mAbs Expenditure in Clinics (Million US$), 2010 & 2011Table 7-4: Japan - Number of Cancer Deaths by Type and Gender (2008 & 2009)Table 7-5: Japan - Approval Date for Key Cancer mAbsTable 7-6: EU - Number of Cancer Cases and Deaths by Type (2008)Table 7-7: EU - Approval Date for Key Cancer mAbsTable 8-1: Global - Anti-Neoplastic mAbs of Key Players in PipelineTable 8-2: Global - Anti-Neoplastic mAbs in Pipeline for Cancer Type by RankTable 9-1: Roche - Key Monoclonal Antibodies in MarketTable 9-2: Roche - Key Monoclonal Antibodies in PipelineTable 9-3: Immunomedics - Key Monoclonal Antibodies in MarketTable 9-4: Immunomedics - Key Monoclonal Antibodies in PipelineTable 9-5: Bristol-Myers Squibb - Key Monoclonal Antibodies in MarketTable 9-6: Bristol-Myers Squibb - Key Monoclonal Antibodies in PipelineTable 9-7: AstraZeneca - Key Monoclonal Antibodies in PipelineTable 9-8: Eli Lilly - Key Monoclonal Antibodies in MarketTable 9-9: Eli Lilly - Key Monoclonal Antibodies in PipelineTable 9-10: Amgen - Key Monoclonal Antibodies in MarketTable 9-11: Amgen - Key Monoclonal Antibodies in PipelineTo order this report:Biopharmaceutical Industry: Cancer Monoclonal Antibodies Market to 2015
MoreMarket Research Report
Check ourIndustry Analysis and Insights
Email: [email protected]
Intl: +1 805-652-2626